ZACTIMA (an Anti-EGFR / Anti-VEGF Agent) Combined With Docetaxel Compared to Docetaxel in Non-small Cell Lung Cancer
Public ClinicalTrials.gov record NCT00312377. Field values are reproduced from the official study page; the official ClinicalTrials.gov record remains the source of truth for eligibility, enrollment, and contact information.
Data is sourced from official ClinicalTrials.gov public API records. Always review the official ClinicalTrials.gov record for the latest information.
Official title
A Phase III, Randomized, Double-Blinded, Multi-Center, Study to Assess the Efficacy of Docetaxel (TAXOTERE™) in Combination With ZD6474 (ZACTIMA™) Versus Docetaxel (TAXOTERE™) With Placebo in Subjects With Locally Advanced or Metastatic NSCLC
Brief summary
Reproduced verbatim from the official ClinicalTrials.gov record. Not medical advice.
This large phase III clinical study is studying the effect of vandetanib (ZACTIMA) in treating non-small cell lung cancer (NSCLC). Vandetanib is a new type of agent that targets the blood supply to a cancer tumour (through it's anti-vascular endothelial growth factor receptor (VEGFR) properties) and the tumour cells themselves (through it's anti-endothelial growth factor receptor (EGFR) actions). This study will look at the effects of vandetanib in lung cancer patients who have had their cancer re-appear after treatment with standard chemotherapy. This clinical study will test if the vandetanib anti-VEGF and anti-EGFR characteristics can deliver longer improved progression free survival and improved overall survival than docetaxel (Taxotere) alone. All patients participating this clinical study will receive treatment with docetaxel, a commonly used treatment for recurrent non-small cell lung cancer. In addition, some patients will also receive vandetanib (ZACTIMA), an anti-EGFR / anti-VEGF agent. Recent clinical research shows that vascular endothelial growth factor receptor (VEGFR) inhibition, when used with standard chemotherapy, can lead to increased survival in advanced non-small cell lung cancer (NSCLC) patients. Other research shows that epidermal growth factor receptor (EGFR) inhibitors, like erlotinib (Tarceva) can also increase overall non-small cell lung cancer survival by killing tumour cells and stopping them from dividing.
Study identification
- NCT ID
- NCT00312377
- Recruitment status
- Completed
- Study type
- Interventional
- Phase
- Phase 3
- Enrollment
- 1,690 participants
Conditions and interventions
Conditions
Eligibility (public fields only)
- Age range
- 18 Years and older
- Sex
- All
- Healthy volunteers
- Healthy volunteers not accepted
This page does not interpret eligibility. Detailed inclusion and exclusion criteria are on the official ClinicalTrials.gov record.
Study timeline
- Start date
- Apr 30, 2006
- Primary completion
- Jul 31, 2008
- Completion
- Feb 28, 2014
- Last update posted
- Sep 29, 2016
2006 – 2014
United States locations
- U.S. sites
- 27
- U.S. states
- 19
- U.S. cities
- 27
| Facility | City | State | ZIP | Site status |
|---|---|---|---|---|
| Research Site | Fullerton | California | — | — |
| Research Site | Los Angeles | California | — | — |
| Research Site | Northridge | California | — | — |
| Research Site | Colorado Springs | Colorado | — | — |
| Research Site | Norwalk | Connecticut | — | — |
| Research Site | Ocala | Florida | — | — |
| Research Site | Marietta | Georgia | — | — |
| Research Site | Joliet | Illinois | — | — |
| Research Site | Park Ridge | Illinois | — | — |
| Research Site | Hutchinson | Kansas | — | — |
| Research Site | Louisville | Kentucky | — | — |
| Research Site | Boston | Massachusetts | — | — |
| Research Site | Ann Arbor | Michigan | — | — |
| Research Site | St Louis | Missouri | — | — |
| Research Site | Henderson | Nevada | — | — |
| Research Site | Albany | New York | — | — |
| Research Site | Armonk | New York | — | — |
| Research Site | New York | New York | — | — |
| Research Site | Durham | North Carolina | — | — |
| Research Site | Hickory | North Carolina | — | — |
| Research Site | Portland | Oregon | — | — |
| Research Site | Austin | Texas | — | — |
| Research Site | Houston | Texas | — | — |
| Research Site | Ogden | Utah | — | — |
| Research Site | Alexandria | Virginia | — | — |
| Research Site | Salem | Virginia | — | — |
| Research Site | Vancouver | Washington | — | — |
Site contact phone numbers, emails, and investigator names are intentionally not displayed here. Open the official ClinicalTrials.gov record for site contact information.
Non-U.S. locations
This page focuses on the U.S. directory. The official record also lists 129 non-U.S. sites.
About this trial record page
- What this page shows
- Public field values for ClinicalTrials.gov record NCT00312377, including study identification, conditions, interventions, eligibility (age, sex, healthy volunteer), timeline, and U.S. site list.
- What this page does not do
- No medical advice, eligibility judgments, treatment recommendations, study quality scoring, or AI-generated medical summaries. No site contact phone numbers, emails, or investigator names.
- Where the data comes from
- Sourced from the official ClinicalTrials.gov public API. The official record is the source of truth.
- Last refresh
- Last update posted Sep 29, 2016 · Synced Sep 3, 2026
Related: full search, browse by condition, browse by drug or therapy, browse by sponsor, browse by U.S. city.
Open the official record
The complete protocol, eligibility criteria, and contact information for NCT00312377 live on ClinicalTrials.gov.